Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

ENO1 promotes Acute Myeloid Leukemia progression through SCD1-mediated lipid metabolism reprogramming

View Full Paper
Ask AI
Bookmark
Share

Authors

YWYijun WuSHShaoyan HuXLXin Liu

Discussion

Loading...

Member takes

Overview

Observational analysis reveals ENO1 influences lipid metabolism and ferroptosis in acute myeloid leukemia, suggesting a therapeutic path with SCD1 inhibition and daunorubicin.

Key Points

  • Increased ENO1 expression correlates with poor prognosis in acute myeloid leukemia.
  • Patients with high ENO1 had lower event-free survival rates compared to those with low ENO1 expression.
  • Analysis of ENO1KD cells showed suppressed tumor growth in vivo and altered lipid metabolic pathways.
  • Combining SCD1 inhibition with daunorubicin may enhance ferroptosis sensitivity in AML cells with elevated ENO1.

Cite This Study

Wu et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dcc0https://doi.org/10.1182/blood-2025-1471
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Alpha-enolase promotes progression of acute myeloid leukemia via MAPK/ERK signaling pathway.2025
  2. 2The role of ENO1 and chidamide in PTCL-NOS2025
  3. 3Ferroptosis escape in AML stem cells uncovered by single-cell profiling and reversed by STAT3/NRF2 inhibition2025
  4. 4Enolase‐1 Is a Key Regulator of Neutrophil Recruitment During Acute Inflammation2025
  5. 5Azin1/tecr reprograms fatty acid metabolism to drive Acute Myeloid Leukemia progression2025